Fidaxomicin Advisory Committee: FDA Wants Advice On The Meaningfulness Of Infection Recurrence
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval of Optimer's antibiotic for C. difficile seems assured, but strength of label remains a question.